JP5599610B2 - Hsp90の阻害による神経変性疾患の処置 - Google Patents

Hsp90の阻害による神経変性疾患の処置 Download PDF

Info

Publication number
JP5599610B2
JP5599610B2 JP2009518602A JP2009518602A JP5599610B2 JP 5599610 B2 JP5599610 B2 JP 5599610B2 JP 2009518602 A JP2009518602 A JP 2009518602A JP 2009518602 A JP2009518602 A JP 2009518602A JP 5599610 B2 JP5599610 B2 JP 5599610B2
Authority
JP
Japan
Prior art keywords
tau
hsp90
brain
protein
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009518602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542716A (ja
JP2009542716A5 (fr
Inventor
チオシス、ガブリエラ
グリーンガード、ポール
ドウ、フェイ
ルオ、ウェンジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JP2009542716A publication Critical patent/JP2009542716A/ja
Publication of JP2009542716A5 publication Critical patent/JP2009542716A5/ja
Application granted granted Critical
Publication of JP5599610B2 publication Critical patent/JP5599610B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009518602A 2006-06-30 2007-07-02 Hsp90の阻害による神経変性疾患の処置 Expired - Fee Related JP5599610B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80642706P 2006-06-30 2006-06-30
US60/806,427 2006-06-30
PCT/US2007/072671 WO2008005937A2 (fr) 2006-06-30 2007-07-02 TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES PAR L'INHIBITION DE Hsp90

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013058040A Division JP5824698B2 (ja) 2006-06-30 2013-03-21 Hsp90の阻害による神経変性疾患の処置

Publications (3)

Publication Number Publication Date
JP2009542716A JP2009542716A (ja) 2009-12-03
JP2009542716A5 JP2009542716A5 (fr) 2010-09-02
JP5599610B2 true JP5599610B2 (ja) 2014-10-01

Family

ID=38895418

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2009518602A Expired - Fee Related JP5599610B2 (ja) 2006-06-30 2007-07-02 Hsp90の阻害による神経変性疾患の処置
JP2013058040A Active JP5824698B2 (ja) 2006-06-30 2013-03-21 Hsp90の阻害による神経変性疾患の処置
JP2015174609A Pending JP2016028063A (ja) 2006-06-30 2015-09-04 Hsp90の阻害による神経変性疾患の処置
JP2017110721A Active JP6427227B2 (ja) 2006-06-30 2017-06-05 Hsp90の阻害による神経変性疾患の処置
JP2018202024A Expired - Fee Related JP6585266B2 (ja) 2006-06-30 2018-10-26 Hsp90の阻害による神経変性疾患の処置

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013058040A Active JP5824698B2 (ja) 2006-06-30 2013-03-21 Hsp90の阻害による神経変性疾患の処置
JP2015174609A Pending JP2016028063A (ja) 2006-06-30 2015-09-04 Hsp90の阻害による神経変性疾患の処置
JP2017110721A Active JP6427227B2 (ja) 2006-06-30 2017-06-05 Hsp90の阻害による神経変性疾患の処置
JP2018202024A Expired - Fee Related JP6585266B2 (ja) 2006-06-30 2018-10-26 Hsp90の阻害による神経変性疾患の処置

Country Status (8)

Country Link
US (5) US10336757B2 (fr)
EP (2) EP3305297A1 (fr)
JP (5) JP5599610B2 (fr)
AU (1) AU2007269144B2 (fr)
CA (1) CA2656202C (fr)
DK (1) DK2034839T3 (fr)
ES (1) ES2645095T3 (fr)
WO (1) WO2008005937A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
EP2038041A4 (fr) * 2006-05-12 2010-02-17 Myriad Genetics Inc Composés thérapeutiques et leur utilisation contre le cancer
AU2007269144B2 (en) * 2006-06-30 2013-05-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
WO2008115719A1 (fr) 2007-03-20 2008-09-25 Curis, Inc. Aminopyridine fondue inhibiteur de hsp90
JP2011503206A (ja) * 2007-11-14 2011-01-27 ミレクシス, インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
PL2318032T3 (pl) 2008-06-26 2012-08-31 Orphazyme Aps Zastosowanie hsp70 jako regulatora aktywności enzymatycznej
WO2010144647A1 (fr) 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Composés de nicotinamide utiles en tant que modulateurs de kinases
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
ES2733131T3 (es) * 2009-10-07 2019-11-27 Sloan Kettering Inst Cancer Res Derivados de purina útiles como inhibidores de hsp90
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
CN103582642B (zh) * 2011-04-05 2021-05-11 索隆-基特林癌症研究协会 Hsp90抑制剂
EA024647B1 (ru) * 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
JP6054389B2 (ja) * 2011-07-08 2016-12-27 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 標識されたhsp90阻害剤の使用
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
US9738643B2 (en) 2012-08-06 2017-08-22 Duke University Substituted indazoles for targeting Hsp90
CN104936953B (zh) 2013-01-23 2017-03-08 阿斯利康(瑞典)有限公司 化合物
CA2905509A1 (fr) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Imagerie cardiaque a ciblage hsp90 et traitement associe
AU2014306417C1 (en) * 2013-08-16 2019-07-25 Memorial Sloan-Kettering Cancer Center Selective Grp94 inhibitors and uses thereof
WO2015038649A1 (fr) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Thérapeutique ciblée
WO2015066053A2 (fr) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Thérapies ciblées
RU2016128528A (ru) 2013-12-23 2018-01-30 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Способы и реактивы для введения радиоактивной метки
WO2015116774A1 (fr) 2014-01-29 2015-08-06 Synta Pharmaceuticals Corp. Agents thérapeutiques cibles
CN106456795A (zh) 2014-03-03 2017-02-22 辛塔医药品有限公司 靶向治疗学
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
EP3193840B1 (fr) 2014-09-15 2021-05-19 Orphazyme A/S Formulation arimoclomol
CN107110869B (zh) 2014-09-17 2021-08-10 纪念斯隆-凯特琳癌症中心 Hsp90-靶向炎症和感染成像及治疗
KR20180058824A (ko) 2015-10-05 2018-06-01 메모리얼 슬로안-케터링 캔서 센터 암 치료를 위한 합리적 병용 요법
WO2017178029A1 (fr) 2016-04-13 2017-10-19 Orphazyme Aps Protéines de choc thermique et homéostasie du cholestérol
US11261187B2 (en) 2016-04-22 2022-03-01 Duke University Compounds and methods for targeting HSP90
AU2017255959B2 (en) 2016-04-29 2020-10-15 Zevra Denmark A/S Arimoclomol for treating glucocerebrosidase associated disorders
RS60209B1 (sr) 2017-03-20 2020-06-30 Forma Therapeutics Inc Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr)
CN110996918A (zh) * 2017-04-24 2020-04-10 萨缪斯治疗股份有限公司 Hsp90抑制剂口服配制品和相关方法
EP3641647A4 (fr) 2017-06-20 2021-05-05 Madrigal Pharmaceuticals, Inc. Agents thérapeutiques ciblés
EP3641782A4 (fr) 2017-06-20 2021-03-24 Madrigal Pharmaceuticals, Inc. Thérapies combinées comprenant des thérapeutiques ciblées
US20210161902A1 (en) * 2017-06-23 2021-06-03 Samus Therapeutics, Inc. Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof
HUE057970T2 (hu) 2018-03-08 2022-06-28 Incyte Corp Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US20220031671A1 (en) 2018-09-19 2022-02-03 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (fr) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activation de la pyruvate kinase r
CA3202568A1 (fr) 2020-11-19 2022-05-27 Zevra Denmark A/S Procedes de preparation de citrate d'arimoclomol et intermediaires associes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903922B2 (ja) 1997-05-14 2012-03-28 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 選択された蛋白質を分解する複合化合物
JP2002541255A (ja) 1999-04-09 2002-12-03 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Her族チロシンキナーゼの分解および/または阻害方法および組成物
US7439359B2 (en) * 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
US20040235813A1 (en) * 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
EP2336133A1 (fr) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Analogues de purine présentant une activité inhibitrice de HSP90
WO2003041643A2 (fr) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Composes de zearalanol inhibant hsp90 et leurs procedes de production et d'utilisation
BR0308056A (pt) 2002-02-28 2004-12-07 Astrazeneca Ab Composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
US7592143B2 (en) 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
WO2005012482A2 (fr) 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Essai d'identification de composes bioactifs qui interagissent avec la proteine du stress 90
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
BRPI0607739A2 (pt) 2005-02-25 2009-09-29 Serenex Inc derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionado
WO2006130469A1 (fr) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation de la croissance des neurites au moyen de molecules de petite taille
US20110263693A1 (en) 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
EP2038041A4 (fr) 2006-05-12 2010-02-17 Myriad Genetics Inc Composés thérapeutiques et leur utilisation contre le cancer
AU2007269144B2 (en) * 2006-06-30 2013-05-16 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
US20100204093A1 (en) 2006-07-27 2010-08-12 University Of Florida Research Foundation, Inc Use of heat shock activators for tissue regeneration
EP2061772A4 (fr) 2006-09-11 2011-06-29 Curis Inc Petites molécules multifonctionnelles servant d'agents anti-prolifératifs
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
US8580519B2 (en) 2006-11-27 2013-11-12 University Of Maryland, Baltimore Use of plasma HSP90 related to malignancy
WO2008115719A1 (fr) 2007-03-20 2008-09-25 Curis, Inc. Aminopyridine fondue inhibiteur de hsp90
US20080234297A1 (en) 2007-03-20 2008-09-25 Changgeng Qian HSP90 Inhibitors Containing a Zinc Binding Moiety
EP2183221A1 (fr) 2007-07-12 2010-05-12 Crystax Pharmaceuticals S.L. Nouveaux composés inhibiteurs de la hsp90
WO2009042646A1 (fr) 2007-09-24 2009-04-02 Curis, Inc. Agents antiprolifératifs
JP2011503206A (ja) 2007-11-14 2011-01-27 ミレクシス, インコーポレイテッド 疾患および障害の治療における治療化合物およびその使用方法
ES2733131T3 (es) 2009-10-07 2019-11-27 Sloan Kettering Inst Cancer Res Derivados de purina útiles como inhibidores de hsp90
EA024647B1 (ru) 2011-04-05 2016-10-31 Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч ИНГИБИТОРЫ Hsp90
CN103582642B (zh) 2011-04-05 2021-05-11 索隆-基特林癌症研究协会 Hsp90抑制剂
AU2014306417C1 (en) 2013-08-16 2019-07-25 Memorial Sloan-Kettering Cancer Center Selective Grp94 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP2034839B1 (fr) 2017-08-23
JP2009542716A (ja) 2009-12-03
JP2019038829A (ja) 2019-03-14
US20240158397A1 (en) 2024-05-16
ES2645095T3 (es) 2017-12-04
AU2007269144A1 (en) 2008-01-10
US20140378452A1 (en) 2014-12-25
WO2008005937A2 (fr) 2008-01-10
US20090298857A1 (en) 2009-12-03
JP6585266B2 (ja) 2019-10-02
CA2656202C (fr) 2018-01-16
JP2016028063A (ja) 2016-02-25
CA2656202A1 (fr) 2008-01-10
US20190389864A1 (en) 2019-12-26
EP2034839A2 (fr) 2009-03-18
JP2017214379A (ja) 2017-12-07
JP5824698B2 (ja) 2015-11-25
JP2013177389A (ja) 2013-09-09
DK2034839T3 (en) 2017-12-04
US20230060990A1 (en) 2023-03-02
WO2008005937A3 (fr) 2008-12-11
US10336757B2 (en) 2019-07-02
EP3305297A1 (fr) 2018-04-11
EP2034839A4 (fr) 2012-08-29
AU2007269144B2 (en) 2013-05-16
JP6427227B2 (ja) 2018-11-21

Similar Documents

Publication Publication Date Title
JP6585266B2 (ja) Hsp90の阻害による神経変性疾患の処置
JP6073377B2 (ja) Gsk−3阻害剤としての新規チアジアゾリジンジオン
JP2009535321A (ja) Gsk−3阻害剤としてのn−(2−チアゾリル)アミド誘導体
JP2011504474A (ja) アルツハイマー氏病を治療するためのMnkインヒビターの使用
US20220313628A1 (en) Methods for selecting phosphatase selective and non-selective phosphatase inhibitors
Hor et al. Beta-propeller protein-associated neurodegeneration (BPAN) as a genetically simple model of multifaceted neuropathology resulting from defects in autophagy
EP3177310A1 (fr) Compositions et méthodes d'identification et de traitement d'états pathologiques impliquant l'activité hsf1
Kesavapany et al. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5
Hartz et al. Discovery of 2-(anilino) pyrimidine-4-carboxamides as highly potent, selective, and orally active glycogen synthase kinase-3 (GSK-3) inhibitors
AU2017200078C1 (en) Treatment of neurodegenerative diseases through inhibition of Hsp90
JP2019501972A (ja) Tdp−43タンパク質症の治療のためのタクロリムス
WO2013149976A1 (fr) Dérivés d'indole-pyrimidine et leurs utilisations thérapeutiques
EP2970118B1 (fr) Composés pour le traitement de troubles neurologiques
EP2662081A1 (fr) Utilisation thérapeutique de dérivés d'indole-dihydro-imidazole
EA025527B1 (ru) Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140813

R150 Certificate of patent or registration of utility model

Ref document number: 5599610

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees